SOUTH SAN FRANCISCO, Calif., July 17 /PRNewswire-FirstCall/ -- VaxGen,
Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today announced
that it has received repayment in full, including accrued interest, of the
bridge loan it extended to Raven biotechnologies Inc. in connection with the
proposed merger between the two companies. The proposed merger was terminated
by mutual consent in March 2008. The total amount received from Raven in
repayment was $6.27 million.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)
About VaxGen
VaxGen is a biopharmaceutical company based in South San Francisco,
California. The company owns a state-of-the-art biopharmaceutical
manufacturing facility with a 1,000-liter bioreactor that can be used to make
cell culture or microbial biologic products. For more information, please
visit the company's web site at http://www.vaxgen.com.
SOURCE VaxGen, Inc.
